Mfg Part Number
Ab03711-2.3

Vector Labs Ab03711-2.3 Anti-IL-20 [h15D2 (Fletikumab)], Mouse IgG2a, Fc Silent™, kappa (100 μg)

Quick Overview
The original antibody was generated by immunizing mice by injecting subcutaneously 20 μg of human IL-20 in FCA followed by two injections with 20 μg of hIL20 in FIA.
$570.70
Order will ship within 1-3 business days
Add to Wish List
Product Class:Purified
Clone ID:h15D2 (Fletikumab)
Heavy Chain Modification:Fc Silent™
Synonyms:IL20; Interleukin-20; ZCYTO10; Cytokine Zcyto10; NN-8226; NNC-0109-0012
Amount:100 μg
Application Codes Clone:ELISA; WB; inhibit; neutralize; therapeutic
Shipping Temperature:Wet Ice
Buffer Composition:PBS with 0.02% Proclin 300.
Original Format:IgG4
Storage Temperature:Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:This antibody binds a linear epitope comprising amino acids 'YQTPDHYTLRKISSLANSFLTIK' of the human Interleukin-20. It also cross reacts with mouse and cynomolgus monkey IL-20 . IL-20 is a pro-inflammatory and angiogenic cytokine mainly secreted by monocytes, granulocytes, dendritic cells and skin keratinocytes that plays crucial roles in immune responses, regulation of inflammatory responses, hemopoiesis, as well as epidermal cell and keratinocyte differentiation. IL-20 shows effects in several inflammatory diseases, such as rheumatoid arthritis, atherosclerosis, cancer, and liver fibrosis via regulating cytokines and chemokines. IL-20 acts on renal cells and contributes to inflammation, fibrosis, and apoptosis through its receptors IL-20R1, IL-20R2, and IL-22R1.
Application Notes:This antibody can bind recombinant human IL-20 in an ELISA. This antibody was capable or neutralizing human IL20, cynomolgus IL20 and mouse IL20 induced proliferation of BaF-3(hIL20R) cells. This antibody can detect both native and denatured form of human IL-20 in a western blot. The original IgG4 version of this antibody, expressed in HEK293 cells, reacts with recombinant human IL-20 with a binding affinity of Kd= 32 pM (US8287861). It shows a very high potency in blocking IL-20 mediated activity on IL-20RA/IL-20RB and IL-22RA1/IL20R2 expressing cells with an IC50 value of 0.27 nM. It has a serum half-life of ~3 weeks in RA (Rheumatoid Arthritis) patients. Under the dose range from 0.05 to 3.0 mg/kg, Fletikumab was tolerable and non-toxic in patients with psoriasis. However, the clinical study was terminated because no apparent efficacy was observed. In the phase 2a trial, Fletikumab significantly reduced tender joint counts and swollen joint counts in seropositive RA patients (PMID: 30319661).
More Information
Brand Vector Labs
UNSPSC 12161500